Rilzabrutinib

The FDA has granted orphan drug designation to rilzabrutinib for IgG4-related disease and warm autoimmune hemolytic anemia, according to a press release from the manufacturer.

SAN DIEGO — Rilzabrutinib induced “fast” and “persistent” platelet count expansion for heavily treated individuals with immune thrombocytopenia, according to results of the randomized phase 3 LUNA 3 study.

SAN DIEGO — Patients with moderate to severe asthma who were treated with rilzabrutinib showed a reduction in loss of asthma control events, according to a study presented at the American Thoracic Society International Conference.

SAN DIEGO — Rilzabrutinib treatment led to rapid, stable and durable platelet responses among patients with relapsed immune thrombocytopenia, according to data presented at ASH Annual Meeting and Exposition.

Rilzabrutinib induced rapid and durable clinical activity in previously treated patients with immune thrombocytopenia, according to results of a phase 1/phase 2 clinical trial published in The New England Journal of Medicine.

The FDA granted fast track designation to rilzabrutinib for treatment of immune thrombocytopenia, according to the agent’s manufacturer.